COMMUNIQUÉS West-GlobeNewswire

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
15/09/2026
Milestone continues the progress towards detection of all 20 amino acids by end of 2026 BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a [...]
PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
15/09/2026
● PDUFA Target Action Date Set for March 16, 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolarityBio ® , a late-stage biotechnology company addressing unmet needs in wound healing through innovation in [...]
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab
15/09/2026
Strategic CDMO collaboration strengthens Axiom’s development infrastructure as the company prepares to advance its therapeutic pipeline. SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage [...]
Ontario Healthcare Stakeholders Unite on Shared Action Plan to Reduce Tobacco and Nicotine Dependence
15/09/2026
Vanguard healthcare, policy, and community stakeholders consolidate as newly formed Ontario Nicotine Action Table (ONAT) to build long-term plan for coordinated action TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- A broad [...]
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that [...]
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
15/09/2026
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a [...]
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
15/09/2026
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE [...]
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
15/09/2026
Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- [...]
Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
15/09/2026
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use ReWalk users with chronic spinal cord injury were able to perform everyday kitchen [...]
Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies
15/09/2026
Eleva Biologics will seek strategic partnerships for development and manufacturing of first-in-class and previously inaccessible biologics discovered with the Bryotechnology platform One04 Therapeutics will focus on [...]
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
15/09/2026
CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathy Detailed interim Phase 1 data to be released in a virtual event after [...]
C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme
15/09/2026
A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis 15 September 2026 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company [...]
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections
15/09/2026
MELBOURNE, Australia, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
Transactions in connection with share buy-back program
15/09/2026
Company announcement no. 35 - 26 15 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026
15/09/2026
Final Phase 1 data provide clinical validation of CBP/p300 as a novel therapeutic target for overcoming transcriptional resistance in NSCLC TT125-802 demonstrates monotherapy anti-tumor activity across biologically [...]
Hummingbird Bioscience Appoints Dr. James Garner as President
15/09/2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“ [...]
Children’s National ranked among top children’s hospitals nationwide and highest in the DMV by U.S. News & World Report
15/09/2026
Ranked in all 11 specialties, with top 10 honors in neurology and neurosurgery, cancer, orthopedics, gastroenterology and GI surgery, neonatology, and diabetes and endocrinology Washington, DC, Sept. 15, 2026 (GLOBE [...]
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
15/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “ Company ” [...]
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
14/09/2026
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage [...]

Pages